SLXNW
Silexion Therapeutics Corp
Price Chart
Latest Quote
$0.03
+0.00 (+7.54%)
Current Price
| Previous Close | $0.03 |
| Open | $0.03 |
| Day High | $0.05 |
| Day Low | $0.03 |
| Volume | 10,254 |
Stock Information
| Total Debt | $1.99M |
| Cash Equivalents | $2.41M |
| Net Income | $-12.91M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Income | $-12.91M |
| Book/sh | $0.83 |
| Employees | 13 |
Financial Ratios
| Quick Ratio | 0.59 |
| Current Ratio | 1.00 |
| Debt/Eq | 683.50 |
Returns & Margins
| ROA | -123.27% |
| ROE | -897.46% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.03 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| RSI | nan |
| ATR | nan |
| Shares Float | 415K |
| Volatility | -0.33 |
| Rel Volume | 20.00 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| YTD | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $nan | 10,254 |
| 2026-06-12 | $0.03 | 0 |
| 2026-06-11 | $0.03 | 0 |
| 2026-06-10 | $0.03 | 0 |
| 2026-06-09 | $0.03 | 0 |
| 2026-06-08 | $0.03 | 0 |
| 2026-06-05 | $0.03 | 0 |
| 2026-06-04 | $0.03 | 0 |
| 2026-06-03 | $0.03 | 0 |
| 2026-06-02 | $0.03 | 0 |
| 2026-06-01 | $0.03 | 0 |
| 2026-05-29 | $0.03 | 0 |
| 2026-05-28 | $0.03 | 0 |
| 2026-05-27 | $0.03 | 0 |
| 2026-05-26 | $0.03 | 0 |
| 2026-05-22 | $0.03 | 0 |
| 2026-05-21 | $0.03 | 0 |
| 2026-05-20 | $0.03 | 0 |
| 2026-05-19 | $0.03 | 0 |
About Silexion Therapeutics Corp
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
đ° Latest News
No news articles available at the moment. Check back later for updates on SLXNW.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $13,000 | $7,000 | $6,000 | - |
| Total Expenses | $11,632,000 | $12,571,000 | $4,681,000 | $3,860,000 |
| Rent Expense Supplemental | $177,000 | $89,000 | $86,000 | $71,000 |
| Other Income Expense | $-406,000 | $903,000 | $-539,000 | $367,000 |
| Other Non Operating Income Expenses | $-279,000 | $1,150,000 | $-86,000 | $1,017,000 |
| Net Non Operating Interest Income Expense | $129,000 | $-4,841,000 | $144,000 | $29,000 |
| Interest Expense Non Operating | $13,000 | $7,000 | $6,000 | - |
| Operating Expense | $11,632,000 | $12,571,000 | $4,681,000 | $3,860,000 |
| General And Administrative Expense | $4,478,000 | $6,731,000 | $928,000 | $577,000 |
| Total Other Finance Cost | - | $4,835,000 | $3,000 | $85,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,912,000 | $-16,443,000 | $-4,942,000 | $-3,215,000 |
| Net Interest Income | $129,000 | $-4,841,000 | $144,000 | $29,000 |
| Interest Income | $142,000 | $1,000 | $153,000 | $114,000 |
| Normalized Income | $-11,814,210 | $-16,252,810 | $-4,593,190 | $-2,714,500 |
| Net Income From Continuing And Discontinued Operation | $-11,912,000 | $-16,443,000 | $-4,942,000 | $-3,215,000 |
| Total Operating Income As Reported | $11,632,000 | $12,571,000 | $-4,681,000 | $-3,860,000 |
| Net Income Common Stockholders | $-11,912,000 | $-16,443,000 | $-4,942,000 | $-3,215,000 |
| Net Income | $-11,912,000 | $-16,443,000 | $-4,942,000 | $-3,215,000 |
| Net Income Including Noncontrolling Interests | $-11,912,000 | $-16,519,000 | $-5,108,000 | $-3,488,000 |
| Net Income Continuous Operations | $-11,912,000 | $-16,519,000 | $-5,108,000 | $-3,488,000 |
| Pretax Income | $-11,909,000 | $-16,509,000 | $-5,076,000 | $-3,464,000 |
| Interest Income Non Operating | $142,000 | $1,000 | $153,000 | $114,000 |
| Operating Income | $-11,632,000 | $-12,571,000 | $-4,681,000 | $-3,860,000 |
| Depreciation Amortization Depletion Income Statement | $14,000 | $25,000 | $45,000 | $57,000 |
| Depreciation And Amortization In Income Statement | $14,000 | $25,000 | $45,000 | $57,000 |
| Depreciation Income Statement | $14,000 | $25,000 | $45,000 | $57,000 |
| Other | ||||
| Tax Effect Of Unusual Items | $-29,210 | $-56,810 | $-104,190 | $-149,500 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,755,000 | $-16,230,000 | $-4,572,000 | $-3,153,000 |
| Total Unusual Items | $-127,000 | $-247,000 | $-453,000 | $-650,000 |
| Total Unusual Items Excluding Goodwill | $-127,000 | $-247,000 | $-453,000 | $-650,000 |
| Reconciled Depreciation | $14,000 | $25,000 | $45,000 | $57,000 |
| EBITDA (Bullshit earnings) | $-11,882,000 | $-16,477,000 | $-5,025,000 | $-3,803,000 |
| EBIT | $-11,896,000 | $-16,502,000 | $-5,070,000 | $-3,860,000 |
| Diluted NI Availto Com Stockholders | $-11,912,000 | $-16,443,000 | $-4,942,000 | $-3,215,000 |
| Minority Interests | $0 | $76,000 | $166,000 | $273,000 |
| Tax Provision | $3,000 | $10,000 | $32,000 | $24,000 |
| Gain On Sale Of Security | $-127,000 | $-247,000 | $-453,000 | $-650,000 |
| Research And Development | $7,140,000 | $5,815,000 | $3,708,000 | $3,226,000 |
| Selling General And Administration | $4,478,000 | $6,731,000 | $928,000 | $577,000 |
| Other Gand A | $2,640,000 | $2,050,000 | $486,000 | $287,000 |
| Rent And Landing Fees | $177,000 | $89,000 | $86,000 | $71,000 |
| Salaries And Wages | $1,661,000 | $4,592,000 | $356,000 | $219,000 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,603,000 | $-3,989,000 | $-15,476,000 | $-10,665,000 |
| Total Assets | $7,215,000 | $2,863,000 | $5,256,000 | $9,333,000 |
| Total Non Current Assets | $578,000 | $613,000 | $277,000 | $494,000 |
| Other Non Current Assets | $57,000 | $48,000 | $25,000 | $25,000 |
| Non Current Prepaid Assets | $84,000 | $5,000 | $5,000 | $5,000 |
| Current Assets | $6,637,000 | $2,250,000 | $4,979,000 | $8,839,000 |
| Other Current Assets | $49,000 | $62,000 | $24,000 | $42,000 |
| Restricted Cash | $27,000 | $35,000 | $25,000 | $25,000 |
| Prepaid Assets | $570,000 | $966,000 | $335,000 | $513,000 |
| Cash Cash Equivalents And Short Term Investments | $5,991,000 | $1,187,000 | $4,595,000 | $8,259,000 |
| Cash And Cash Equivalents | $5,991,000 | $1,187,000 | $4,595,000 | $8,259,000 |
| Debt | ||||
| Total Debt | $2,036,000 | $4,491,000 | $171,000 | $271,000 |
| Long Term Debt And Capital Lease Obligation | $1,854,000 | $3,329,000 | $59,000 | $156,000 |
| Long Term Debt | $1,568,000 | $2,961,000 | - | - |
| Current Debt And Capital Lease Obligation | $182,000 | $1,162,000 | $112,000 | $115,000 |
| Net Debt | - | $2,778,000 | - | - |
| Current Debt | - | $1,004,000 | - | - |
| Other Current Borrowings | - | $1,004,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,612,000 | $6,852,000 | $17,312,000 | $16,412,000 |
| Total Non Current Liabilities Net Minority Interest | $1,854,000 | $3,329,000 | $15,116,000 | $14,802,000 |
| Current Liabilities | $2,758,000 | $3,523,000 | $2,196,000 | $1,610,000 |
| Payables And Accrued Expenses | $1,697,000 | $1,717,000 | $1,677,000 | $1,239,000 |
| Payables | $838,000 | $976,000 | $319,000 | $240,000 |
| Total Tax Payable | $51,000 | $47,000 | - | - |
| Income Tax Payable | $51,000 | $47,000 | - | - |
| Accounts Payable | $787,000 | $929,000 | $319,000 | $240,000 |
| Other Current Liabilities | - | $2,000 | $200,000 | $3,000 |
| Equity | ||||
| Common Stock Equity | $2,603,000 | $-3,989,000 | $-15,476,000 | $-10,665,000 |
| Total Equity Gross Minority Interest | $2,603,000 | $-3,989,000 | $-12,056,000 | $-7,079,000 |
| Stockholders Equity | $2,603,000 | $-3,989,000 | $-15,476,000 | $-10,665,000 |
| Retained Earnings | $-55,166,000 | $-43,254,000 | $-26,811,000 | $-21,869,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $15,057,000 | $14,646,000 |
| Other | ||||
| Ordinary Shares Number | $312,665 | $12,324 | $6,038 | $6,038 |
| Share Issued | $312,665 | $12,326 | $6,038 | $6,038 |
| Tangible Book Value | $2,603,000 | $-3,989,000 | $-15,476,000 | $-10,665,000 |
| Invested Capital | $4,171,000 | $-24,000 | $-15,476,000 | $-10,665,000 |
| Working Capital | $3,879,000 | $-1,273,000 | $2,783,000 | $7,229,000 |
| Capital Lease Obligations | $468,000 | $526,000 | $171,000 | $271,000 |
| Total Capitalization | $4,171,000 | $-1,028,000 | $-15,476,000 | $-10,665,000 |
| Additional Paid In Capital | $57,727,000 | $39,263,000 | $11,335,000 | $11,203,000 |
| Capital Stock | $42,000 | $2,000 | $0 | $1,000 |
| Common Stock | $42,000 | $2,000 | $0 | $1,000 |
| Long Term Capital Lease Obligation | $286,000 | $368,000 | $59,000 | $156,000 |
| Current Capital Lease Obligation | $182,000 | $158,000 | $112,000 | $115,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $879,000 | $642,000 | $207,000 | $253,000 |
| Current Accrued Expenses | $859,000 | $741,000 | $1,358,000 | $999,000 |
| Net PPE | $437,000 | $560,000 | $247,000 | $464,000 |
| Accumulated Depreciation | $-83,000 | $-69,000 | $-87,000 | $-239,000 |
| Gross PPE | $520,000 | $629,000 | $247,000 | $703,000 |
| Other Properties | $412,000 | $530,000 | $247,000 | $582,000 |
| Machinery Furniture Equipment | $108,000 | $99,000 | $77,000 | $69,000 |
| Treasury Shares Number | - | $2 | - | - |
| Minority Interest | - | $0 | $3,420,000 | $3,586,000 |
| Leases | - | $0 | $56,000 | $52,000 |
| Properties | - | $0 | $0 | $0 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,828,000 | $-8,418,000 | $-4,541,000 | $-3,375,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-10,819,000 | $-8,396,000 | $-4,529,000 | $-3,335,000 |
| Cash Flow From Continuing Operating Activities | $-10,819,000 | $-8,396,000 | $-4,529,000 | $-3,335,000 |
| Operating Gains Losses | - | $16,000 | $-1,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-9,000 | $-22,000 | $-12,000 | $-40,000 |
| Investing Cash Flow | $-14,000 | $-22,000 | $573,000 | $-524,000 |
| Cash Flow From Continuing Investing Activities | $-14,000 | $-22,000 | $573,000 | $-524,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $18,680,000 | $3,054,000 | $522,000 | $2,749,000 |
| Financing Cash Flow | $15,640,000 | $5,104,000 | $522,000 | $2,752,000 |
| Cash Flow From Continuing Financing Activities | $15,640,000 | $5,104,000 | $522,000 | $2,752,000 |
| Net Other Financing Charges | $-2,344,000 | $2,300,000 | - | - |
| Net Preferred Stock Issuance | $2,644,000 | $0 | $522,000 | $2,749,000 |
| Preferred Stock Issuance | $2,644,000 | $0 | $522,000 | $2,749,000 |
| Net Common Stock Issuance | $16,036,000 | $3,054,000 | $0 | - |
| Common Stock Issuance | $16,036,000 | $3,054,000 | $0 | - |
| Other | ||||
| Repayment Of Debt | $-696,000 | $-250,000 | $0 | - |
| Interest Paid Supplemental Data | $13,000 | $27,000 | - | - |
| End Cash Position | $6,075,000 | $1,270,000 | $4,645,000 | $8,309,000 |
| Beginning Cash Position | $1,270,000 | $4,645,000 | $8,309,000 | $10,083,000 |
| Effect Of Exchange Rate Changes | $-2,000 | $-61,000 | $-230,000 | $-667,000 |
| Changes In Cash | $4,807,000 | $-3,314,000 | $-3,434,000 | $-1,107,000 |
| Net Issuance Payments Of Debt | $-696,000 | $-250,000 | $0 | - |
| Net Long Term Debt Issuance | $-696,000 | $-250,000 | $0 | - |
| Long Term Debt Payments | $-696,000 | $-250,000 | $0 | - |
| Net Investment Purchase And Sale | $-5,000 | $0 | $507,000 | $-484,000 |
| Purchase Of Investment | $-5,000 | $0 | $0 | $-500,000 |
| Net PPE Purchase And Sale | $-9,000 | $-22,000 | $66,000 | $-40,000 |
| Purchase Of PPE | $-9,000 | $-22,000 | $-12,000 | $-40,000 |
| Change In Working Capital | $601,000 | $-1,580,000 | $87,000 | $239,000 |
| Change In Other Working Capital | $232,000 | $378,000 | $-40,000 | $-87,000 |
| Change In Other Current Assets | $13,000 | $-38,000 | $18,000 | - |
| Change In Payables And Accrued Expense | $-40,000 | $-1,289,000 | $438,000 | $-49,000 |
| Change In Accrued Expense | $102,000 | $-1,899,000 | $359,000 | $-11,000 |
| Change In Payable | $-142,000 | $610,000 | $79,000 | $-38,000 |
| Change In Account Payable | $-142,000 | $610,000 | $79,000 | $-38,000 |
| Change In Prepaid Assets | $396,000 | $-631,000 | $-329,000 | $415,000 |
| Other Non Cash Items | $344,000 | $3,800,000 | $318,000 | $-268,000 |
| Stock Based Compensation | $134,000 | $5,862,000 | $130,000 | $125,000 |
| Depreciation Amortization Depletion | $14,000 | $25,000 | $45,000 | $57,000 |
| Depreciation And Amortization | $14,000 | $25,000 | $45,000 | $57,000 |
| Depreciation | $14,000 | $25,000 | $45,000 | $57,000 |
| Gain Loss On Sale Of PPE | $0 | $16,000 | $-1,000 | $0 |
| Net Income From Continuing Operations | $-11,912,000 | $-16,519,000 | $-5,108,000 | $-3,488,000 |
| Sale Of Investment | - | $0 | $507,000 | $16,000 |
| Sale Of PPE | - | $0 | $78,000 | $0 |
| Proceeds From Stock Option Exercised | - | - | $0 | $3,000 |
| Change In Receivables | - | - | $18,000 | $-40,000 |
Fetched: 2026-06-19